Translocation-mediated transcriptional activation of tyrosine kinase gene ABL1 is implicated in the pathogenesis of chronic myeloid leukemia. Notch1 encodes a member of the Notch family and is a transmembrane receptor including an extracellular domain consisting of multiple epidermal growth factor-like repeats

and an intracellular domain consisting of multiple, different domain types. The Notch signaling pathway is involved in a variety of cellular differentiation, proliferation, and apoptosis [33]. Enjin et al. reported that human osteosarcoma cell lines and primary human osteosarcoma tumor samples showed significant upregulation of Notch1 [34]. TNC is an oligomeric selleck screening library glycoprotein of the extracellular matrix that is involved in embryogenesis, tumorigenesis, and angiogenesis. Of note, Franchi et al. reported that TNC expression was found in MFH [35]. However, the role of these genes in the development and progression of pleomorphic MFH is NOD-like receptor inhibitor unknown. The p16 INK4A gene is located at 9p21. This gene is frequently mutated or deleted in a variety of tumors and is known to

be an important tumor suppressor gene [36]. Frequent deletions of p16 INK4A have also been reported in pleomorphic MFH [37]. However, the association between p16 INK4A alterations and prognosis in pleomorphic MFH patients remains controversial [1]. In the present study, we decided to examine this gene using metaphase FISH analysis because loss of 9p21-pter was detected by CGH. As expected, homozygous deletion of p16 INK4A was observed in FU-MFH-2 cell line. Taken together, these findings suggest that inactivation of p16 INK4A by homozygous selleck chemicals llc crotamiton deletion may be important for pleomorphic MFH development, although

not tumor-type specific. Conclusion We described the establishment and characterization of a new permanent human cell line, FU-MFH-2, derived from a metastatic pleomorphic MFH. The FU-MFH-2 will be useful for various biologic and molecular pathogenetic studies of human pleomorphic MFH. Acknowledgements This work was supported in part by Kaibara Morikazu Medical Science Promotion Foundation, Japan Orthopaedics and Traumatology Foundation, Fukuoka Cancer Society, Clinical Research Foundation, and a Grant-in-Aid for Young Scientists (B) (21791424) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. References 1. Fletcher CDM, van den Berg E, Molenaar WM: Pleomorphic malignant fibrous histiocytoma/undifferentiated high grade pleomorphic sarcoma. In WHO Classification of Tumours, Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by: Fletcher CDM, Unni KK, Mertens F. IARC Press: Lyon, France; 2002:120–122. 2. Shirasuna K, Sugiyama M, Miyazaki T: Establishment and characterization of neoplastic cells from a malignant fibrous histiocytoma. A possible stem cell line. Cancer 1985, 55: 2521–2532.PubMedCrossRef 3.